Sign inJoin waitlistJoin the waitlist

John Reagan

Director of Hematology, Brown University Health Cancer Institute · Alpert Medical School

Credentials: · · · · ·

History

Alpert Medical School
Present

Hematology and Medical Oncology
SUNY Upstate Medical University
2009–2012
Internal Medicine
Rhode Island Hospital/Brown University Health
2006–2009
Alpert Medical School
2002–2006

Research

Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies
Systematic review or meta-analysis · Blood · 2012 · 164 citations
Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single…
The Journal of Immunology · 2004 · 137 citations
Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83
Blood · 2004 · 123 citations

Adam Olszewski
24 papers
Jorge Castillo
17 papers
Peter Quesenberry
13 papers
James Butera
11 papers
Eric Winer
9 papers
AH
Andrew Hsu
7 papers · 7 as a fellow
Thomas Ollila
7 papers · 4 as a fellow
Diana Treaba
6 papers
PB
Peter Barth
6 papers · 2 as a fellow
Adam Zayac
5 papers · 5 as a fellow
IS
Ilyas Sahin
5 papers · 5 as a fellow
Pamela Egan
5 papers · 1 as a fellow

Clinical trials

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1, Phase 2
Brown University
2019–2025
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Site PI · Recruiting · Phase 2, Phase 3
Moleculin Biotech, Inc.
2025–2030
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029